Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP6160)
Name
Cyanidin-3-O-glucoside chloride
Synonyms
Kuromanine; 7084-24-4; Chrysontemin; Glucocyanidin; Cyanidin 3-glucoside; Cyanidin-3-glucoside chloride; Kuromanin chloride; Cyanidol 3-glucoside; Kuromanin (chloride); Cyanidin 3-monoglucoside; UNII-8X15R84UEM; CYANIDIN 3-GLUCOSIDE CHLORIDE; Chrysanthemin; cyanidin-3-glucoside; 8X15R84UEM; 2-(3,4-Dihydroxyphenyl)-3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-1-benzopyrylium chloride; cyanidin-3-O-glucoside; cyanidin-3-o-glucoside chloride; Cyanidine 3-glucoside; KUROMANIN; Cyanidin 3 glucoside; EINECS 230-384-7; Chrysanthemin (6CI,8CI); 47705-70-4; SCHEMBL158216; (2S,3R,4S,5S,6R)-2-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromenylium-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride; HY-N0640; MFCD27665410; Cyanidin 3-O-glucopyranoside chloride; cyanidin-3-O-beta-d-galactopyranoside; AKOS022185309; CS-5203; 1-Benzopyrylium, 2-(3,4-dihydroxyphenyl)-3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-, chloride; 1-Benzopyrylium, 5,7-dihydroxy-2-(3,4-dihydroxyphenyl)-3-(beta-D-glucopyranosyloxy)-, chloride; AS-56225; N2562; Q-100788; Q5114535; UNII-F02KPB2508 component YTMNONATNXDQJF-UBNZBFALSA-N; UNII-R911H793SU component YTMNONATNXDQJF-UBNZBFALSA-N; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-3-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)chromenylium
    Click to Show/Hide
Species Origin Chrysanthemum argyrophyllum ...     Click to Show/Hide
Chrysanthemum argyrophyllum
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Asterales
Family: Asteraceae
Genus: Chrysanthemum
Species: Chrysanthemum argyrophyllum
Disease Breast cancer [ICD-11: 2C60] Investigative [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C21H21ClO11
PubChem CID
197081
Canonical SMILES
C1=CC(=C(C=C1C2=[O+]C3=CC(=CC(=C3C=C2OC4C(C(C(C(O4)CO)O)O)O)O)O)O)O.[Cl-]
InChI
1S/C21H20O11.ClH/c22-7-16-17(27)18(28)19(29)21(32-16)31-15-6-10-12(25)4-9(23)5-14(10)30-20(15)8-1-2-11(24)13(26)3-8;/h1-6,16-19,21-22,27-29H,7H2,(H3-,23,24,25,26);1H/t16-,17-,18+,19-,21-;/m1./s1
InChIKey
YTMNONATNXDQJF-UBNZBFALSA-N
CAS Number
CAS 7084-24-4
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Cisplatin      Bladder cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Up-regulation Expression BAX  Molecule Info 
Pathway MAP
Down-regulation Expression BCL-2  Molecule Info 
Pathway MAP
Down-regulation Expression GABPA  Molecule Info 
Pathway MAP
                    In-vitro Model HeLa CVCL_0030 Endocervical adenocarcinoma Homo sapiens
                    Experimental
                    Result(s)
Potentiation of DDP with C3G improves cancer cell susceptibility, specifically cervical cancer cells, to DDP.
References
Reference 1 Cyanidin-3- O-glucoside chloride acts synergistically with luteolin to inhibit the growth of colon and breast carcinoma cells. Pharmazie. 2019 Jan 1;74(1):54-61.
Reference 2 Combination of cyanidin-3-O-glucoside and cisplatin induces oxidative stress and apoptosis in HeLa cells by reducing activity of endogenous antioxidants, increasing bax/bcl-2 mRNA expression ratio, and downregulating Nrf2 expression. J Food Biochem. 2021 Jul;45(7):e13806.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China